Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
LETTER
doi:10.1038/nature13968
RoleofTP53mutationsintheoriginandevolutionoftherapy-relatedacutemyeloidleukaemia
TerrenceN.Wong1*,GiridharanRamsingh2*,AndrewL.Young3*,ChristopherA.Miller4,WaseemTouma1,JohnS.Welch1,5,TamaraL.Lamprecht1,DongShen6,JasreetHundal4,RobertS.Fulton4,SharonHeath1,JackD.Baty7,JefferyM.Klco8,LiDing1,5,ElaineR.Mardis4,5,9,PeterWestervelt1,5,JohnF.DiPersio1,5,MatthewJ.Walter1,5,TimothyA.Graubert1,5,TimothyJ.Ley1,5,ToddE.Druley3,DanielC.Link1,5&RichardK.Wilson4,5,9
Therapy-relatedacutemyeloidleukaemia(t-AML)andtherapy-relatedmyelodysplasticsyndrome(t-MDS)arewell-recognizedcomplicationsofcytotoxicchemotherapyand/orradiotherapy1.Thereareseveralfeaturesthatdistinguisht-AMLfromdenovoAML,includingahigherincidenceofTP53mutations2,3,abnormalitiesofchromosomes5or7,complexcytogeneticsandareducedresponsetochemotherapy4.However,itisnotclearhowpriorexposuretocytotoxictherapyinflu-encesleukaemogenesis.Inparticular,themechanismbywhichTP53mutationsareselectivelyenrichedint-AML/t-MDSisunknown.Here,bysequencingthegenomesof22patientswitht-AML,weshowthatthetotalnumberofsomaticsingle-nucleotidevariantsandtheper-centageofchemotherapy-relatedtransversionsaresimilarint-AMLanddenovoAML,indicatingthatpreviouschemotherapydoesnotinducegenome-wideDNAdamage.Weidentifiedfourcasesoft-AML/t-MDSinwhichtheexactTP53mutationfoundatdiagnosiswasalsopresentatlowfrequencies(0.003–0.7%)inmobilizedbloodleuko-cytesorbonemarrow3–6yearsbeforethedevelopmentoft-AML/t-MDS,includingtwocasesinwhichtherelevantTP53mutationwasdetectedbeforeanychemotherapy.Moreover,functionalTP53muta-tionswereidentifiedinsmallpopulationsofperipheralbloodcellsofhealthychemotherapy-naiveelderlyindividuals.Finally,inmousebonemarrowchimaerascontainingbothwild-typeandTp531/2hae-matopoieticstem/progenitorcells(HSPCs),theTp531/2HSPCspre-ferentiallyexpandedafterexposuretochemotherapy.ThesedatasuggestthatcytotoxictherapydoesnotdirectlyinduceTP53muta-tions.Rather,theysupportamodelinwhichrareHSPCscarryingage-relatedTP53mutationsareresistanttochemotherapyandex-pandpreferentiallyaftertreatment.TheearlyacquisitionofTP53mutationsinthefoundingHSPCcloneprobablycontributestothefrequentcytogeneticabnormalitiesandpoorresponsestochemo-therapythataretypicalofpatientswitht-AML/t-MDS.
t-AMLandt-MDSareclonalhaematopoieticdisordersthattypicallydevelop1–5yearsafterexposuretochemotherapyorradiotherapy1.TounderstandbetterhowpriorcytotoxictherapycontributestothehighincidenceofTP53mutationsandkaryotypicabnormalitiesint-AML/t-MDS,wesequencedthegenomesof22casesoft-AML,includingonecasethathasbeenpreviouslyreported5.Thesedatawerecomparedtowhole-genomesequencedatapreviouslyreportedfordenovoAML6andsecondaryAML(s-AML)arisingfromMDSforwhichpatientsdidnotreceivechemotherapyexcepthydroxyurea7,8.Ofthesequencedt-AMLcases,23%hadrearrangementsofMLL(alsoknownasKMT2A),23%hadcomplexcytogenetics,and36%hadnormalcytogenetics(ExtendedDataTable1andSupplementaryTable1).
WepredictedthatDNAdamageinducedduringexposuretocyto-toxictherapywouldmanifestitselfint-AMLgenomeswithanincreased
1
mutationburden.However,thetotalnumberofvalidatedsomaticsingle-nucleotidevariants(SNVs)andgenic(tier1)somaticSNVsidentifiedwassimilartothatfordenovoAMLands-AML(Fig.1a,b).Likewise,thenumberofsmallinsertionsordeletions(indels)ingenicregionswassimilarint-AML,denovoAMLands-AML(Fig.1c).Apreviousstudy
a
Total somatic SNVs
b
Tier 1 SNVs
cTier 1 indelsd
Transversions (%)
AML
e
AML
f
AML
Mutation type (%)
Number of clones
AMLL
Ls-AM
Mt-A
vo
no
g
Percentage with mutationDe
C
to GA to TC to CA to GC to T
A to
A
h
Percentage with mutation
ABTP5C3ST FmAG2PTKIPNTPK1H1PKD1UDL22AFTE1T2IDRUH1NNRAIX1S/DHKR2AFSNLT3DNPMM1T3A
Figure1|Themutationalburdenint-AMLissimilartodenovoAML.a,Totalnumberofvalidatedtier1–3somaticSNVsint-AML(n522),denovoAML(n549)ands-AML(n58).Themeanagesofthet-AML,denovoAMLands-AMLcohortswere55.7,51and54.6years,respectively.b,Numberofvalidatedtier1somaticSNVs.c,Numberofvalidatedtier1smallindels.d,Percentageoftier1–3somaticSNVsthataretransversions.e,Mutationalspectrumforallvalidatedtier1–3somaticSNVs.f,Numberofdistinctclonespersampleinferredfromtheidentificationofdiscreteclustersofmutationswithdistinctvariantallelefrequencies.g,Percentageofcasesoft-AML(n552)ordenovoAML(n5199)harbouringnon-synonymousmutationsoftheindicatedgene.h,Percentageofcasesoft-MDS(n559)ordenovoMDS(n5150)harbouringnon-synonymousmutationsoftheindicatedgene.ABCFm,ABCfamilygenes;NA,notavailable.{P,0.05byone-wayanalysisofvariance(ANOVA).*P,0.05byFisher’sexacttest.Datarepresentthemean6standarddeviation(s.d.).
DepartmentofMedicine,DivisionofOncology,WashingtonUniversity,StLouis,Missouri63110,USA.2DepartmentofMedicine,JaneAnneNohlDivisionofHematology,UniversityofSouthernCalifornia,LosAngeles,California90089,USA.3DepartmentofPediatrics,DivisionofHematology/Oncology,WashingtonUniversity,StLouis,Missouri63110,USA.4TheGenomeInstitute,WashingtonUniversity,StLouis,Missouri63110,USA.5SitemanCancerCenter,WashingtonUniversity,StLouis,Missouri63110,USA.6AstraZeneca,Gaithersburg,Maryland20878,USA.7DivisionofBiostatistics,WashingtonUniversity,StLouis,Missouri63110,USA.8DepartmentofPathologyandImmunology,WashingtonUniversity,StLouis,Missouri63110,USA.9DepartmentofGenetics,WashingtonUniversity,StLouis,Missouri63110,








USA.
*Theseauthorscontributedequallytothiswork.
00MONTH2014|VOL000|NATURE|1
TRUP53ABNXC1U Fm2AASF1OXLBS1EZCNNRAEH2S/TVKR6BCASSTORAGDNN2MF1T3TEAT2
highgrade malignancy and resistance to therapy ?...The accumulation of mutations can be accelerated ...The role of TP53 is central guardian of the ...
progression and high response rates to therapy. ...the role of these mutations in FL pathogenesis. ...Clonal evolution of a follicular lymphoma: evidence...
evolution 增生中的细胞 蜇伏的细胞 Properties of ...mutations as they divide, accounting for the ...(致癌基因) Growth factors and related hormones ...
highgrade malignancy and resistance to therapy ?...The accumulation of mutations can be accelerated ...The role of TP53 is central guardian of the ...
predisposition related to germline mutations exists ...TP53 is located on 17p but its role in the ... acute myeloid leukemia, neuroblastoma, and in ...
cancer-related mortality in women worldwide, with ...Somatic mutations in TP53 and PIK3CA were each ...et al. Mutational evolution in a lobular breast ...
in the evolution of gliomas Hiroko Ohgaki1 and ...pathways and the role of glial precursor cell ...TP53 mutations are signi?cantly more frequent in...
Mutations of the BRAF gene in human cancer_...a-melanocyte stimulating-hormone and other related ...evolution (with the exception of the BRAF V599 ...
The evolution of gene re... 11页 1财富值 ...Indeed, somatic mutations of TP53, the gene ...and characterizing related phenotypes, has been ...
Activating mutations in KRAS are present in the ...To model anti-Ras therapy, we and others have ...To assess the possible role of Yap1, Birc2 ...
热门文档